COVID-19 Therapeutics (antivirals, neutralising monoclonal antibodies and interleukin 6 inhibitors)

This section contains information on the total number of COVID-19 therapeutics (antivirals – ‘AVs’, neutralising monoclonal antibodies – ‘nMABS’, and interleukin 6 – ‘IL-6’ inhibitors) provided by the NHS in England to:

    • Eligible individuals hospitalised due to COVID-19, or with hospital-onset COVID-19 in England between 11 July 2020 and 26 June 2023.
    • Eligible non-hospitalised individuals in England with COVID-19 between 16 December 2021 and 26 June 2023.

These data are as reported from information submitted by NHS hospitals and COVID Medicine Delivery Units (CMDUs) treating patients (via a system called Blueteq) when an individual is determined to be clinically eligible for (and agrees to) treatment.



Weekly AV, nMAB and IL-6 inhibitor treatments administered/dispensed.

This publication shows the total number of individuals identified as eligible to receive AVs, nMABs or IL-6 inhibitors who received such treatment each week and presents hospital-based treatment figures separately to non-hospitalised patient treatment figures.

This publication shows the total number of treatments administered in England between 11 July 2020 and 26 June 2023 (for hospital-based treatment figures) or 16 December 2021 and 26 June 2023 (for non-hospitalised based treatment figures) reported every 7 days (week ending each Sunday).

Figures relate to all individuals who received relevant treatments either as an inpatient, or via COVID Medicine Delivery Units (CMDUs) in England.

The figures do not include information relating to such treatments administered as part of clinical trials (for example the PANORAMIC trial).

This publication includes breakdowns of the numbers of COVID therapeutic treatments by the specific treatment.

Following the publication of the positive NICE recommendations for NHS COVID treatments, nationally co-ordinated pandemic specific arrangements have now been stood down. Integrated Care Boards (ICBs) are responsible for ensuring routine access to nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (Actemra) for eligible patients. All national reporting requirements ended on 26 June.

Please note that during the period 29 March to 26 June there may be some reduction in data completeness and quality due to changes in responsibilities following the publication of the NICE recommendations on COVID Therapeutics.

The final COVID Therapeutics Weekly Publication was published on 6 July 2023.

COVID Therapeutics Weekly Publication (week ending 2nd July 2023)(XLSX, 221KB)

A one off data release has also been produced to provide insight into the number of digitally identified potentially eligible patients who went on to receive treatment in England. These individuals were primarily treated and/or assessed via CMDUs, though some were treated and/or assessed in hospital. These data are given nationally and regionally, weekly and on average from December 2021 to end of March 2023.

COVID-19 Therapeutics supplementary data release: Antivirals and neutralising-monoclonal antibodies (AVs and nMABs): Proportion of digitally identified non-hospitalised patients treated(XLSX, 77KB)

Data Notes and further information

Information relating to the digital identification of individuals who were considered potentially eligible for AV or nMAB treatment can be found here:

Treatments for coronavirus (COVID-19) (


Further information for clinicians can be found here:

COVID-19 community-based treatments (


Information for patients regarding current treatment options can be found here:

Treatments for COVID-19 (